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A. Abstracts 
A.1 Summary 
Macular pucker (MP) and vitreomacular traction syndrome (VMTS) are traction 
vitreoretinopathies that develop at the vitreoretinal terface of the macular area. The major 
component of the vitreoretinal interface is the intr al limiting membrane (ILM), which is the 
site of epiretinal membrane (ERM) formation mediating tractional forces from the vitreous to 
retinal layers. Removal of the ILM/ERM represents a principal goal of vitreoretinal surgery in 
MP and VMTS. Recently, a new preparation method of surgically excised ILM specimens 
was proposed. The new flat-mount preparation method has numerous advantages compared to 
conventional cross-sectioning preparation procedures. Most importantly, it allows for 
showing the maximum area of a tissue specimen with en-face observation of the total cell 
distribution. 
 
By using 119 flat-mounted ILM specimens with epiretinal tissue removed en-bloc during 
vitrectomy from eyes with MP and VMTS, we performed phase contrast and interference 
microscopy, LIVE/ DEAD viability assay, and indirect immunostaining by using 16 
antibodies directed against glial cells, hyalocytes, r tinal pigment epithelial cells, retinal 
ganglion cells and extracellular matrix components. The specimens were removed from 119 
eyes of 117 patients including 79 eyes with MP and 40 eyes with VMTS. Intraoperatively, the 
state of the vitreous was assessed regarding the pres nce of complete or incomplete posterior 
vitreous detachment (PVD).  
 
Since specimens from MP with complete PVD were found with significantly higher cell 
viability than specimens from MP with incomplete PVD and VMTS, we raise the hypothesis 
that the extent of PVD and the presence of vitreoretinal adhesions with traction forces at the 
retina may have some influence on cell viability of epiretinal cells. In this study, we found 
two cell distribution patterns. Specimens from MP demonstrated with homogenous cell 
distribution and cell cluster formation. In specimens from VMTS, cell cluster formation was 
predominant. We hypothesize that epiretinal cell pro iferation may be initiated by localized 
vitreoretinal traction forming cell clusters that progress to homogenous cell multilayers at the 
vitreal side of the ILM after a period of time.  
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Immunocytochemical analysis demonstrated predominant st ining for glial cell and hyalocyte 
marker such as GFAP, vimentin, CRALBP, CD45, and CD163. Myofibroblast-like cells with 
positive α-SMA expression were frequently found, whereas anti-cytokeratin, -Kir4.1, -CD34, 
-CD68, and -Ki67 were sparsely distributed in this series. Anti-neurofilament and -GAP43 
were negative in all specimens tested. Anti-fibronectin, -laminin, and -collagen type IV were 
positive irrespective of the group of disease. Based on our results, we support the hypothesis 
that glial cells, notably retinal Müller cells, and hyalocytes are important components of 
epiretinal membranes in both MP and VMTS.  
 
Most importantly, we found co-localizations of glial cell and hyalocyte marker and co-
localization of anti-α-SMA with the hyalocyte marker anti-CD163. It appears that GFAP 
labeling in epiretinal cell proliferation needs to be reconsidered since positive GFAP labeling 
no longer allows for determination of cells to be of glial origin. Cells with double labeling for 
anti-GFAP and hyalocyte markers may represent hyaloc tes. However, it is unknown if these 
‘hyalocytes’ express GFAP endogenously or if they contain GFAP from other origin due to 
their well-known phagocyte activity. Another hypothesis is that double labeled cells may 
represent progenitor cells of transdifferentiated clls.  
 
Co-localization of anti-CD163/α-SMA was seen in this study which supports the hypothesis 
that hyalocytes are able to transdifferentiate intomyofibroblast-like cells in epiretinal 
membranes. Since positive α-SMA labeled epiretinal cells mainly presented in MP with 
incomplete PVD and VMTS, we hypothesize that the ext nt of PVD with persistent 
vitreoretinal adhesions may play an important role in differentiation of epiretinal cells and 
their antigen expression in eyes with MP and VMTS. Further investigation is needed to 
elucidate the influence of persistent vitreoretinal adhesions on behavior of hyalocyte cell 
populations, thereby addressing the role of cell transdifferentiation and the presence of 
progenitor cells in epiretinal membranes. 
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A.2   Zusammenfassung  
Traktive Makulopathien wie die fortgeschrittene Form der epiretinalen Gliose, auch Macular 
pucker (MP) genannt, und das vitreomakuläre Traktionssyndrom (VMTS) entstehen an der 
vitreoretinalen Grenzfläche der Macula. Hauptkomponente der vitreoretinalen Grenzfläche ist 
die innere Grenzmembran, die Membrana limitans interna (ILM), die antero-posterior und 
tangential gerichtete Traktionen auf die Netzhaut überträgt. Diese mechanischen Zugkräfte 
entstehen durch persistierende Adhärenzen des Glaskörpers und durch epiretinale 
fibrozelluläre Membranen (ERM) an der vitrealen Seite der ILM. Die Entfernung von ILM 
und ERM ist daher wesentliches Ziel der vitreoretinale  Chirurgie bei MP und VMTS. Eine 
neue Präparationsmethode zur Aufbereitung von chirurgisch gewonnenen ILM-Präparaten 
bietet wichtige Vorteile gegenüber der konventionellen Einbettungs- und Schnittpräparation. 
Die neue Flachpräparation erlaubt die Darstellung des gesamten ILM-Präparates in seiner 
gesamten Größe mit vollständigem Zellbesatz. 
 
Einhundertneunzehn ILM-Präparate wurden zusammen mit epiretinalem Gewebe während 
der Vitrektomie von 117 Patienten mit MP und VMTS gewonnen. Wir führten eine 
Flachpräparation mit Phasenkontrast- und Interferenzmikroskopie, LIVE/ DEAD ® 
Viabilitätsanalyse sowie indirekte immunzytochemische Färbungen mit 16 Antikörpern durch, 
die zellspezifisch gegen Gliazellen, Hyalozyten, retinale Pigmentepithelzellen und 
extrazelluläre Matrixkomponenten gerichtet waren. Insgesamt wurden die ILM-Präparate von 
79 Augen mit MP und 40 Augen mit VMTS analysiert. Das Vorliegen einer kompletten oder 
inkompletten hinteren Glaskörperabhebung (PVD) wurde intraoperativ dokumentiert. 
 
Die Viabilität zellulärer Proliferationen in Präparaten von MP mit kompletter PVD war 
signifikant höher als bei Präparaten von MP mit inkompletter PVD und VMTS. Während 
Präparate von MP eine homogene Zellverteilung als auch Zellclusterformationen zeigten, 
waren Zellcluster in Präparaten von VMTS häufiger. Persistierende Glaskörperadhärenzen 
mit vitreoretinaler Traktion, wie sie im Rahmen einer inkompletten PVD bestehen, könnten 
daher an der Ausbildung epiretinaler Zellcluster initial beteiligt sein und sowohl die 
Progression zellulärer Proliferationen als auch die Zellviabilität mitbestimmen. 
 
Zellmarker für Gliazellen und Hyalozyten wie anti-GFAP, -Vimentin, -CRALBP, -CD45 und 
-CD163 prädominierten in allen Präparaten. Myofibroblasten-ähnliche Zellen mit positiver α-
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SMA Färbung wurden ebenfalls häufig gefunden. Anti-Zytokeratin, -Kir4.1, -CD34, -CD68, 
and -Ki67 wurden selten positiv nachgewiesen. Anti-Neurofilament and -GAP43 wurden in 
unseren Präparaten nicht gesehen. Anti-Fibronectin, -Laminin, and -Kollagen Typ IV waren 
zumeist positiv unabhängig von der Grunderkrankung. Basierend auf unseren Ergebnissen 
gehen wir davon aus, dass Gliazellen, insbesondere retinale Müller Zellen, und Hyalozyten 
wichtige zelluläre Komponenten epiretinaler Membranen bei MP und VMTS darstellen.  
 
Bedeutsam erscheint uns der Nachweis von Zellmarker-Doppelfärbungen. Co-Lokalisationen 
von Antikörpern spezifisch für Gliazellen und Hyalozyten wurden häufig gefunden, während 
die Co-Lokalisation von anti-α SMA mit dem Hyalozytenmarker anti-CD163 selten auftrat. 
Wir gehen davon aus, dass die Interpretation positiver GFAP-Färbungen erneut überdacht 
werden sollte, da die alleinige positive Darstellung von anti-GFAP in immunzytochemischen 
Färbungen nicht länger als Grundlage für die Zuordnung von epiretinalen Zellen zu 
Populationen glialen Ursprungs dienen kann. Doppelfärbungen von anti-GFAP und 
Hyalozytenmarkern stellen vermutlich Hylozyten dar. Unklar bleibt jedoch, ob diese 
‚Hyalozyten’ GFAP endogen exprimieren oder ob sie GFAP extrazellulären Ursprungs 
enthalten als Zeichen ihrer phagozytären Aktivität. Eine weitere Hypothese ist, dass GFAP-
positive ‚Hyalozyten’ Progenitorzellen oder transdifferenzierte Zellen mit unbekannter 
Antigenexpression darstellen. 
 
Über Doppelfärbungen von anti-α-SMA/CD163 in epiretinalen Membranen wurde bisher 
nicht berichtet. Unsere Ergebnisse stützen die Hypothese, dass Hyalozyten in 
Myofibroblasten-ähnliche Zellen transdifferenzieren. Da positive α-SMA gefärbte epiretinale 
Zellen vorwiegend in Präparaten von MP mit inkompletter PVD und VMTS gesehen wurden, 
gehen wir davon aus, dass persistierende vitreoretinal  Adhärenzen eine wichtige Rolle bei 
der Differenzierung epiretinaler Zellen und ihrer Antigenexpression spielen. Weitere 
Untersuchungen müssen zeigen, ob und in welcher Weise vitreoretinale Traktionen das 
Verhalten von epiretinalen Zellen verändert. Dabei könnte insbesondere die 
Transdifferenzierung epiretinaler Zellproliferationen und das Vorkommen von 
Progenitorzellen in epiretinalen Membranen im Mittelpunkt stehen. 
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B. Abbreviations 
 
BBG Brilliant blue G 
CD cluster of differentiation 
CRALBP cellular retinaldehyde binding protein 
DAPI 4’, 6-diamidino-2-phenylindole 
ERM epiretinal membrane 
EthD-1 ethidium homodimer-1 
GAP43 growth associated protein 43 
GFAP glial fibrillary acidic protein 
ILM internal limiting membrane 
MB Membrane blue 
MP macular pucker 
NF neurofilament 
OCT optical coherence tomography 
PBS phosphate buffered saline 
PBTA phosphate buffered triton azid 
PPV pars plana vitrectomy 
PVD    posterior vitreous detachment 
RMC          retinal Müller cell 
RNFL       retinal nerve fiber layer  
RPE retinal pigment epithelium 
SD       standard deviation 
α-SMA α-smooth muscle actin 
SPSS        statistical package for the social science 
TB    Trypan blue  
VMTS       vitreomacular traction syndrome 
 
Introduction 
6                                                                                                                                                                               
1. Introduction  
Progressive epiretinal gliosis, such as macular pucker (MP), and vitreomacular traction 
syndrome (VMTS) are traction vitreoretinopathies that develop at the vitreoretinal interface of 
the macular area. The major component of the vitreoretinal interface is the internal limiting 
membrane (ILM) that has attracted enormous interest for decades. The ILM is the site of 
epiretinal membrane formation and mediates tractional forces from the vitreous to retinal 
layers. There is general consent that vitreoretinal raction plays a crucial role in the 
pathogenesis and the clinical course of MP and VMTS. [Morris, 2000] Antero-posterior 
vitreoretinal traction is caused by persistent vitreoretinal adhesions due to an incomplete 
posterior vitreous detachment (PVD), whereas tangential traction is caused by contractive 
epiretinal membranes (ERMs) due to progressive fibrocellular proliferation at the vitreal side 
of the ILM. [Zarbin, 1990; Koerner, 1999; Gandorfer, 2005; Wylegala, 2006; Sebag, 2008] 
 
Removal of the vitreous and epiretinal tissue is a principal goal of vitreoretinal surgery in MP 
and VMTS since epiretinal membranes represent the morphological correlate of typical 
symptoms found in these diseases, such as reduction of visual acuity and metamorphopsia. 
[Trese, 1983; Koerner, 1999] The concept of peeling off the ILM in eyes with traction 
maculopathies is supported by numerous studies reporting on improved functional and 
anatomic outcome. Furthermore, vitreoretinal surgery with ILM/ERM peeling was shown to 
minimize the recurrence rate of epiretinal cell proliferation. [Park, 2003; Kwok, 2004; Kwok, 
2005; Tari, 2007] Therefore, ILM/ERM removal is a procedure widely accepted in the 
therapy of traction maculopathies.  
  
By light and electron microscopic analysis, several studies characterized epiretinal cells and 
extracellular matrix components. According to their r sults, various cell types such as glial 
cells, hyalocytes, retinal pigment epithelial (RPE) cells, and fibroblast-like cells appear to be 
important in ERM formation. [Kampik, 1980; Gandorfer, 2002; Tari, 2007; Schumann, 2010] 
However, the specific role of epiretinal cell proliferation at the ILM in traction maculopathies 
is still a matter of debate. Even investigations of cell type specific antigen expressions of 
epiretinal cells did not allow for identifying the c lls’ origin exactly which is most probably 
caused by phenotypic transdifferentiation of epiretinal cells that adopt features of other cell 
types. To date, there is no specific marker of transdifferentiated cells [Vinores, 1990]. 
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Recently, a new preparation method, the flat-mounted pr paration of whole ILM/ERM 
specimens, was proposed to overcome limits of conventional serial sectioning preparation 
procedures. [Hisatomi, 2005; Hisatomi, 2006; Gandorfer, 2009; Liu, 2009] By preparing flat-
mounted ILM specimens, the whole specimen can be visualized en-face, thereby detecting 
even small single cells on the ILM that would probably not be observed by conventional 
sectioning procedures. By using flat-mounted ILM/ERM specimens removed en-bloc during 
vitrectomy from eyes with MP and VMTS, the aim of our study was to obtain more accurate 
details on epiretinal cell proliferation with regard to cell distribution, cell viability, and cell 
immunoreactivity. 
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1.1 Anatomy of the vitreoretinal interface 
The vitreoretinal interface (Figure 1.1), defined as morphological structure between the 
posterior vitreous cortex and the plasma membrane of r tinal Müller cells (RMCs), consists of 
three components: (1) posterior vitreous cortex fibrils, (2) the ILM and (3) Müller cell 
footplates adjacent to the retinal side of the ILM. [Sebag, 1991; Gandorfer, 2004; Schumann, 
2006; Schumann, 2007; Johnson, 2010] 
1.1.1 Vitreous  
The outer surface of the vitreous, the hyaloid membrane, is in contact with the posterior lens 
capsule, the zonular fibers, the pars plana epithelium, the retina, and the optic nerve head. The 
base of the vitreous maintains a firm attachment throughout life to the pars plana epithelium 
and the retina immediately behind the ora serrata. [Balazs, 1964; Ramesh, 2004] The vitreous 
composes of about 97% - 99% fluid. The remaining comp nents are a mixture of collagen 
fibrils and hyaluronic acid, hyalocytes, inorganic salts and lipids that give the vitreous a gel-
like form and consistency. [Scott, 1992] There are connections between vitreous collagen and 
the ILM. Vitreous collagen fibrils insert into the ILM, being most intense at the vitreous base 
and in some areas of the vitreous cortex. Recently, vi reous cortex was shown to be 
immunoreactive for collagen type II, V, IX and XI. [Sebag, 1992; Ponsioen, 2008] 
1.1.2 Retinal Müller cells 
Retinal Müller cells (RMCs) are the main type of glial cells in the retina that span the entire 
thickness of the retina and ensheath all retinal neurons. With retinal injury, RMCs are thought 
to become activated, to dedifferentiate and migrate from the retinal side to the vitreal side of 
the ILM where they proliferate and may drive epiretinal membrane formation. [Bringmann 
and Wiedemann, 2009] RMCs provide highly specialized physiological properties to support 
neurons in structure, nutrition and metabolism. Thus any impairment of supportive functions 
of them could cause and/or aggravate the dysfunction and loss of neurons. [Bringmann, 2006; 
Bringmann, 2009; Eberhardt, 2011] Vitreoretinal trac ion is considered to cause RMC 
activation. Activated Müller cells are known to upregulate the expression of glial fibrillary 
acidic protein (GFAP) that otherwise is not or very faintly expressed by RMC under normal 
conditions. [Lewis, 2003]  
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1.1.3 Internal limiting membrane 
The internal limiting membrane (ILM), also termed basal lamina of the retina or internal 
limiting lamina, is an acellular structure that mainly composed of collagen type IV, VI and 
XVIII. [Heegaard, 1997; Ponsioen, 2008]  It is thought to be the basement membrane of 
RMCs. The ILM typically shows a smooth vitreal side adjacent to the vitreous cortex and an 
undulated retinal side adjacent to RMC endfeet. The ILM is composed of three structures 
similar to other basement membranes: lamina fibroreticularis, lamina densa and lamina lucida. 
[Foos, 1972] The thickness of the ILM was found with regional difference in human adult 
eyes, being thickest at the macular region and thinnest at the ora serrata region. [Heegaard, 
1997]   
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Figure 1.1  
 
 
Figure 1.1 Transmission electron micrographs of the vitr oretinal interface and 
the retinal nerve fiber layer (RNFL) of the retina. The vitreal side (arrow) of 
the ILM (asterisk) is smooth, whereas the retinal side of the ILM presents with 
typical undulations corresponding to interdigitating processes of retinal Müller 
cell (RMC) footplates embedded in the RNFL. (Unpublished images of the 
Laboratory for Electron Microscopy, Department of Ophthalmology, Ludwig-
Maximilians-University, Munich, by courtesy of Dr. med. R.G. Schumann.) 
(Original magnification: (A) x1, 800; (B) x9, 500) 
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1.2 Pathogenesis  
1.2.1 Posterior vitreous detachment  
Posterior vitreous detachment (PVD) is associated with (1) vitreous liquefaction and 
accumulation of fluid in the premacular portion of the vitreous cavity, and (2) incomplete or 
complete detachment of the posterior vitreous cortex f om the ILM with varying degrees of 
persistent vitreoretinal adhesions. An anomalous PVD, called vitreoschisis, results from a 
split in the posterior vitreous cortex layers. As a consequence, residual vitreous collagen 
fibers are left behind at the vitreal side of the ILM and residual islands of cortical vitreous 
remain attached to the ILM following separation of the majority of vitreous gel from the 
surface of the retina. [Sebag, 2004; Sebag, 2008] Vitreoretinal traction of the retina caused by 
incomplete PVD may allow for activation and migration of glial cells from the inner retina to 
the surface of the ILM, where they are thought to proliferate and form epiretinal membranes. 
[Foos, 1978; Bringmann and Wiedemann, 2009] 
 
Posterior vitreous detachment is associated with a variety of vitreoretinal pathologies, 
depending upon whether or not the posterior vitreous detachment is intact (full thickness) or 
split (partial thickness) which means complete or incomplete. [Sebag, 2008] Vitreoschisis was 
suggested to be pathogenic in MP. [Gupta, 2011] In VMTS, full-thickness vitreous cortex 
adherences to the macula with peripheral vitreoretinal separation induce vitreomacular 
traction. [Gandorfer, 2002; Sebag, 2008]  
1.2.2 Macular pucker  
Macular pucker (MP) (Figure 1.2) is a progressive form of epiretinal gliosis characterized by 
massive fibrocellular proliferation at the vitreal side of the ILM forming a dense, grayish-
white appearing epiretinal membrane that causes severe tangential traction at the retina with 
retinal folding and distortion of retinal vessels. Retinal folds radiate in uni- or multi-
directional fashion in the macular area, mostly towards the epicenter of the epiretinal 
membrane. Retinal traction can cause tortuosity of he perimacular vessels, macular edema, 
and intraretinal bleeding. According to density and contractility of epiretinal cell proliferation, 
milder forms of epiretinal gliosis are defined as cellophane maculopathy and surface 
wrinkling maculopathy referring to a thin, glistening membrane with or without superficial 
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retinal folds. Epiretinal membranes are a common finding in older patients that mostly occur 
in the absence of any ocular pathology. However, epi etinal gliosis may be associated with 
other ocular disorders and after intraocular surgery. [Cox, 1995; Jacobsen, 1996; Jahn, 1999; 
Katira, 2008] In MP, patients usually complain of severe vision loss and metamorphopsia. 
[Dellaporta, 1973; Tari, 2007] Bowing and blurring when looking at lines on chart paper 
(Amsler grid) are noticed by patients with retinal folding in the vitreous area. Retinal imaging 
technique such as optical coherence tomography (OCT), fundus photography and fluorescein 
angiography are used to enhance accuracy of MP diagnosis. [Sebag, 2007] 
1.2.3 Vitreomacular traction syndrome  
Vitreomacular traction syndrome (VMTS) (Figure1.3) is a vitreomacular disorder 
characterized by a firm and persistent vitreoretinal adhesion in eyes with an incomplete PVD. 
The vitreous is detached in the periphery whereas the vitreous remains attached to the macula 
and the optic nerve head, thereby causing vitreoretinal traction with macular edema and 
peripapillary edema that may progress to cystoid retinal degeneration. Patients complain of 
moderate to severe loss of vision and metamorphopsia. [McDonald, 1994; Figus, 2008] 
Incomplete PVD varies from peripheral vitreous separation with residual foveal attachment to 
multiple areas of detachment with focal posterior and peripheral vitreous attachment. Once 
thought to be a rare distinct clinical entity, VMTS is now considered a spectrum of macular 
diseases. [Shechtman, 2009] Although the clinicopathologic correlation with different 
features of VMTS has not been determined yet, the predominance of myofibroblasts was 
reported that may induce the progressive VMTS characte istic in this disorder. [Shinoda, 2000; 
Gandorfer, 2002] 
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Figure 1.2   Macular pucker                                 Figure 1.3 Vitreomacular traction syndrome 
             
Figure 1.2 and 1.3 Retinal imaging of eyes with MP and VMTS. (A) Fluorescein 
angiography and (B) fundus photography show retinal vessel tortuosity in MP and 
VMTS. (C) OCT images demonstrate the presence of the ERMs and vitreomacular 
traction (arrows) in MP and VMTS. (Photographs by courtesy of the Department of 
Ophthalmology, Ludwig-Maximilians-University, Munich) 
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1.3   Cells implicated in the pathogenesis of vitreoretinal 
maculopathies 
Morphological analyses of surgically excised ILM specimens have demonstrated a variety of 
cells in epiretinal membranes of idiopathic vitreortinal maculopathies that are thought to be 
of retinal and extra-retinal origin including glial cells (Müller cells, astrocytes, and microglia), 
retinal pigment epithelial cells, hyalocytes, fibrocytes and myofibroblasts. [Kampik, 1981; 
Smiddy, 1989; Gandorfer, 2005; Schumann, 2006] 
1.3.1 Retinal glial cells  
Retinal glial cells included macroglia (RMCs and astrocytes) and microglia. Retinal Müller 
cells are the main type of glial cells in the retina, which have been introduced above in 1.1.2. 
 
Astrocytes are a sub-type of glial cells in the retina. They are also known as astrocytic glial 
cells. They possess a star shape with numerous processes enveloping synapses of neurons. 
They migrate into the retina via the optic nerve during embryogenesis, and are located 
exclusively in the inner layers of the retina. [Watanabe, 1988; Sandercoe, 1999] Like Müller 
cells, astrocytes are also considered to dedifferentiat , proliferate, and migrate from the retinal 
side to the vitreous side of the ILM where they may p rticipate in ERM formation. [Ramírez, 
1996] Immunohistochemical findings suggested that astrocytes also express GFAP similar to 
activated RMCs in ERMs. [Sandercoe, 1999]    
 
Microglial cells account for approximately 20% of the total glial cell population in the central 
nervous system. They belong to the mononuclear phagocyte system and constitute the 
population of resident macrophages in the brain and the retina. Activated microglia cells 
become immunocompetent and are MHC (major histocompatibility complex) class 1 and 
class 2 positive. [Kreutzberg, 1995; Huang, 2008] Microglia activation is associated with 
CD68 (cluster of differentiation 68) immunoreactivity. [Wang, 2010] In response to injury, 
microglia cells undergo rapid activation and produce both proinflammatory and regenerative 
neurotrophic factors. [Ng, 2009; Ibrahim, 2011]  
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Recent years increasing effort focused in assessing the plasticity of glial cells as a potential 
source for new neurons in the injured eye. Following injury, RMCs are proposed to 
differentiate and acquire stem or precursor cell like properties. [Bringmann, 2009; Berninger, 
2010] 
1.3.2 Retinal pigment epithelial cells  
Retinal pigment epithelial (RPE) cells are multifunctional pluripotent cells that are 
characterized by intracytoplasmic melanin granules, microvilli and junctional complexes. 
RPE cells have various functions. Most importantly, they participate in cell metabolism of 
photoreceptors, and they are related to vitamin A metabolism and regeneration in the visual 
cycle. Retinal pigment epithelium cells are capable of phagocytosis. [Uchida, 2005; Strauss, 
2009] Additionally, they are proposed to possess immunosuppressive properties. [Sugita, 
2009; Sugita, 2010]  
1.3.3 Hyalocytes 
Hyalocytes, first described in 1845 by Hannover andthen named by Balazs, are resident cells 
distributed in the vitreous cortex situated 20 – 50 µm apart from the ILM. [Hannover, 1845; 
Balazs, 1964; Sebag, 1992] Hyalocytes most probably derive from the monocytes-
macrophage lineage, and appear to be involved in the pathogenesis of various vitreoretinal 
diseases. They are thought to mediate ERM contractility. [Hirayama, 2004; Kohno, 2009] 
Other origins have also been proposed such as derivations from neuroglia of the retina, from 
mesenchymal cells of the retinal vasculature, and from cells of the hyaloid system. [Sebag, 
1992] Hyalocytes were shown to express the leukocyte-associated antigens CD45, CD64 and 
ED2 (CD163). [Lazarus, 1994; Zhu, 1999; Sakamoto, 2003; Qiao, 2005] 
1.3.4 Myofibroblasts 
Myofibroblasts are found subepithelially in many mucosal surfaces. They are known to 
participate in wound-healing, inflammation or fibrosis of non-neoplastic conditions, and in 
tumor growth. Myofibroblasts are of spindled or satellite morphology and share features with 
fibroblasts in Golgi apparatus and expression of smooth muscle actin. However, they are 
devoid of lamina-α structures seen in smooth muscle cells [Eyden, 2001; Eyden, 2009]. 
Myofibroblasts were reported to be present or even pr dominant in the vitreoretinal disorders 
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such as MP and VMTS. Their immunophenotype is characte ized by α-smooth muscle actin 
(α-SMA). [Gandorfer, 2002; Ina, 2011] 
1.3.5 Macrophages 
Macrophages are white blood cells deriving from differentiation of monocytes in tissues. 
Macrophages function in non-specific defense (innate immunity) as well as in specific 
defense mechanisms (adaptive immunity) of vertebrat animals. They stimulate lymphocytes 
and other immune cells to respond to pathogens. [Streit, 2001] Macrophages express of the 
cell type associated antigen CD68. However, to datethere is no specific marker to 
differentiate between macrophages and microglial cells. [Bosman, 1999; Khazen, 2005] 
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1.4   Surgical Treatment 
1.4.1 Pars plana vitrectomy 
Pars plana vitrectomy (PPV) is generally agreed to be the most appropriate treatment for 
vitreoretinal disorders. In early 1970s, the original purpose of vitrectomy was to remove 
clouded vitreous. In 1991, Kelly and Wendel introduced PPV to close macular holes. 
Meanwhile the removal of the ILM during vitrectomy is recommended in most vitreomacular 
diseases. Numerous studies have approved that vitrectomy improves visual acuity in at least 
70% of individuals with MP and VMTS [Kelly, 1991; Koerner, 1999]. 
1.4.2 Vital dyes in vitreoretinal surgery 
Vital dyes help to visualize translucent structures such as the ILM and ERM in vitreoretinal 
surgery, and therefore, they facilitate ILM removal. Recently, this technique was named 
‘chromovitrectomy’ [Rodrigues, 2005]. Brilliant Blue G (BBG) was suggested to stain the 
ILM safely. Other dyes, such as Trypan Blue (TB) or Membrane Blue (MB) were introduced 
to stain epiretinal tissue providing only a weak contrast of the ILM. [Enaida, 2006; Haritoglou, 
2008; Schumann, 2010]  
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1.5 Immunomarker mentioned in this study 
1.5.1 CD163  
CD163, also called ED2, recognizes membrane and cytoplasmic antigens of tissue 
macrophages, discriminating between distinct subpopulations of macrophages/monocytes. 
[Yang, 2002] Immunofluorescent analysis of rat eyes showed that 90% of hyalocytes were 
positive for ED2 [Sakamoto, 2003].  
1.5.2 CD45       
CD45, also known as protein tyrosine phosphates (PTPRC), is an enzyme that was originally 
called leukocyte common antigen in hematopoietic cells. It is expressed among hematopoietic 
cells, and is also expressed constitutively in hyalocytes and microglia. [Kaplan, 1990; Lazarus, 
1994; Zhu, 1999]  
1.5.3 Glial fibrillary acidic protein   
Glial fibrillary acidic protein (GFAP) is an intermediate filament protein that was thought to 
be specific for glial cells in the past. It is closely related to its non-epithelial family member’s 
vimentin, desmin, and peripherin, which are all involved in the structure and function of the 
cell’s cytoskeleton. The up-regulation of GFAP is the most sensitive response of Müller cells 
to retinal injury, and can be used as marker for Müller cell activation. Its exact function 
remains poorly understood. [Guérin, 1990; Bongcam-Rudloff, 1991; Lewis, 2003; Lesnik 
Oberstein, 2008; Middeldorp, 2011] 
1.5.4 Vimentin  
Vimentin is a member of the intermediate filament family of proteins that is especially found 
in connective tissue. Intermediate filaments are an important structural feature of eukaryotic 
cells. Along with microtubules and actin microfilaments, they generate the cytoskeleton. 
Although most intermediate filaments are stable structures, in fibroblasts vimentin exists as a 
dynamic structure. This filament protein is used as a marker for mesodermally derived cells, 
such as retinal glial cells, fibroblasts, endothelial cells, lymphoid cells and melanocytes. 
[Fuchs, 1994; Lesnik Oberstein, 2008; Bhatia, 2009; Semple-Rowland, 2010] 
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1.5.5 Cellular retinaldehyde binding protein  
Cellular retinaldehyde binding protein (CRALBP) is encoded by the retinaldehyde binding 
protein (RLBP1) gene in humans. It is a functional component of the visual cycle. This gene 
was found in RPE cells and Müller cells of the neuroretina. [Maw, 1997; Limb, 2002; Walcott, 
2003; Collery, 2008] 
1.5.6 Kir4.1                
Kir4.1 may form a heterodimer with another potassium channel protein and may be 
responsible for the potassium buffering action of glial cells in the brain. Retinal Müller glial 
cells, astrocytes, RPE cells may be able to be distinguished by diminished presence of the 
integral membrane protein Kir4.1. [Connors, 2006; Hu, 2010] Kir4.1 is found on RMCs 
endfeet membranes and is involved in inhibition of glial cell growth. [Higashimori, 2007; 
Ruiz-Ederra, 2007] 
1.5.7 α-Smooth muscle actin     
Alpha-smooth muscle actin (α-SMA) is one of six different actin isoforms that have been 
identified. Actins are highly conserved proteins that are involved in cell motility, structure 
and integrity of cells. Its expression is associated with the presence of myofibroblasts, 
epithelial cells, striated muscle cells and myocardium. [Harris, 1992] 
1.5.8 Cytokeratin  
Cytokeratins (CKs) are proteins of keratin-containing intermediate filaments found in the 
intracytoplasmic cytoskeleton of epithelial tissue. [Franke, 1979] For detecting cytokeratins, 
pan-cytokeratin antibody with the clone designation C11 is frequently used as the marker of 
RPE cells [Fuchs, 1991; Boyd, 2009]. 
1.5.9 Growth associated protein 43  
Growth associated protein 43 (GAP43) is considered as a crucial component of the axon and 
presynaptic terminal. This protein is abundant during development but absent in normal retina. 
It is used to identify neuronal growth cones during development and axonal regeneration. In 
Introduction 
20 
the retina, GAP43 is involved in synapse formation. Ganglion cells show an elevated 
expression of GAP43 after ischemia-inflicted damage. [Fisher, 2005; Dijk, 2007; Kusik, 2010] 
1.5.10 Neurofilament 
Neurofilament (NF) is the 10 nm intermediate filaments found specifically in neurons. The 
subunits of neurofilament protein are related structurally to intermediate filaments of other 
tissues such as the keratin subunits in epithelia. The level of neurofilament gene expression 
seems to be directly related to the neurons (axons) f the central and peripheral nervous 
system, and may be a useful tool for the identification of ganglion cells and bipolar cells. 
[Lesnik Oberstein, 2008] 
1.5.11 CD34     
CD34 molecule is a cell surface glycoprotein and functions as a cell-cell adhesion factor. It 
may also mediate the attachment of stem cells to bone marrow extracellular matrix or directly 
to stromal cells. It is expressed on the surface of lymphohematopoietic cells, stem and 
progenitor cells, small vessel endothelial cells and embryonic fibroblasts. [Simmons, 1992; 
Satterthwaite, 1992; Sandercoe, 1999]  
1.5.12 CD68 
CD68 is a glycoprotein which binds to low density lpoprotein. It is expressed in 
monocytes/macrophages. [Holness, 1993; Manduch, 2009] Activated microglia cells also 
express the CD68 antigen. [Yang, 2000; Wang, 2010] To date, there is no specific marker to 
differentiate between macrophages and microglia. 
1.5.13 Collagen IV  
Type IV collagen is a type of collagen found primarily in the basal lamina. It lacks the regular 
glycine in every third residue necessary for the tight collagen helix. This makes the overall 
arrangement sloppier with kinks that cause the collagen to form a sheet. [Khoshnoodi, 2008] 
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1.5.14 Fibronectin    
Fibronectin (FN) is a high-molecular weight extracellular matrix glycoprotein that binds to 
membrane-spanning receptor proteins called integrins. In addition to integrins, it also binds 
extracellular matrix components such as collagen, fibrin and heparan sulfate proteoglycans. 
Fibronectin plays a major role in cell adhesion, cell growth, migration and differentiation, and 
it is important for wound healing. Fibronectin immunoreactivity can be found in retinal 
vessels. [Hiscott, 1992; Roy, 1996; Pankov, 2002; Chen, 2009] 
1.5.15 Laminin   
Laminins are major proteins in the basal lamina, a protein network foundation for most cells 
and organs. They are an important and biologically active part of the basal lamina, influencing 
cell differentiation, migration, adhesion, and cell survival. Studies showed that human ERMs 
from patients of varying durations were immunoreactive for laminin. [Timpl, 1979; Lesnik 
Oberstein, 2008; Chen, 2009] 
1.5.16 Ki67                        
Antigen Ki67 is a nuclear protein that is associated with cellular proliferation. It is an 
excellent marker to determine the growth fraction of a given cell population since it is 
expressed in proliferating cells. Studies showed that Ki67-positive proliferating cells were 
present in undifferentiated retina, but not in differentiated retina. [Schonk, 1989; 
Heidenkummer, 1992; Walcott, 2003]
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Table 1.1   Correlation of antibodies used in this study andimmunospecificity 
 
Immunomarker Immunospecificity 
CD163 hyalocytes 
CD45 hyalocytes, microglia 
GFAP glial cells (Müller cells, astrocytes) 
Vimentin glial cells 
CRALBP Müller cells, retinal pigment epithelial cells 
Kir4.1 glial cells 
α-SMA myofibroblasts, epithelial cells 
Cytokeratin retinal pigment epithelial cells 
GAP43 axonal regeneration, regenerated ganglion cells 
Neurofilament retinal ganglion cells and bipolar cells 
CD34 endothelial cells, stem cells 
CD68 macrophages, microglia, monocytes 
Collagen IV internal limiting membrane 
Fibronectin cell adhesion, migration, differentiation 
Laminin cell adhesion, migration, differentiation 
Ki67 cell proliferation  
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2. Material and Methods 
2.1 Laboratory equipment 
           
(1)  Refrigerator                                                 (2) Incubator 
(BOSCH, Germany)                                      (Memermt, Schwabach, Germany) 
 
 
 
              
(3)  Electronic balance scout pro SPU 202         (4) Shaker IKA-VIBRAZ-VXR 
(Ohaus, Pine Brook, NJ USA)                        (IKA, Staufen, Germany) 
 
Metrials and Methods 
24 
                                       
 (5) Fluorescence microscope LEICA MS5                (6) Captair® chem Filtair 
 (Leica, Wetzlar, Germany)                                   (erlab, Köln, Germany) 
 
 
 
                                        
(7) Light microscope Leica DM2500                        
(Leica, Wetzlar, Germany)                               
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2.2 Reagents  
Aqua dest. (Braun 6724092) 
0.5% BSA (SIGMA A-9647, Taufkirchen, Germany) 
Donkey Cy2   (Dianova, Hamburg, Germany) 
Donkey Cy3 (Dianova, Hamburg, Germany) 
Donkey Cy5 (Dianova, Hamburg, Germany) 
Donkey serum   (Dianova, Hamburg, Germany) 
ImmnunoSelect® Antifading Mounting Medium DAPI      
 (Dianova AKS-38448, Hamburg, Germany) 
LIVE/ DEAD ® Viability/ Cytotoxicity Kit * for mammalian cells *     
 (Molecular Probes L-3224, Invitrogen, Carlsbad, USA) 
3.4% NaCl    (Pharmacy of Ludwig-Maxmilians University, N18) 
Na2HPO4        (MERCK 1.06346, Darmstadt, Germany) 
Na2H2PO4 (MERCK 1.06580, Darmstadt, Germany) 
0.1% Na-Azid (SIGMA S-8032, Taufkirchen, Germany) 
Paraformaldehyd   (MERCK 1.04005, Darmstadt, Germany) 
Pepsin   (Sigma-Aldrich P7000, Taufkirchen, Germany) 
PBS Buffer   (Pharmacy of Ludwig-Maxmilians University, G09) 
0.1% Triton X-100 (SIGMA X-100, Taufkirchen, Germany) 
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2.3 Prescriptions 
2.3.1 Phosphate buffered saline (PBS) 0.1M 
Na2HPO4 – 2H2O                  14.42g 
Na2H2PO4 – H2O                   2.62g  
Distilled water                      1000 ml 
Adjust to PH 7.4 with HCl 
2.3.2 Paraformaldehyde (PFA) 
Paraformaldehyde                   2g 
0.1M PBS                              50ml 
80°C heat for 15 min 
Place in the 4°C refrigerator 
2.3.3 Enzyme 
10% Pepsin                             1000µl 
0.1M PBS                               1ml  
Place in the -20°C refrigerator 
2.3.4 Phosphate buffered triton azid (PBTA) 
0.1 M PBS (Ph7.4)                 100ml 
0.5% BSA                              500µg 
0.1% Triton X-100                 100 µl 
0.1% Na-Azid                        100mg 
Place in the -20°C refrigerator 
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2.4 Antibodies 
CD163    (SantaCruz sc-58965, Heidelberg, Germany) 
CD45 (SantaCruz sc-1123, Heidelberg, Germany)  
GFAP (DAKO Z0334, Glostrup, Denmark) 
vimentin (DAKO M0725, Glostrup, Denmark) 
CRALBP (SantaCruz sc-18757, Heidelberg, Germany) 
Kir4.1 (SantaCruz sc-23637, Heidelberg, Germany) 
α-SMA (SIGMA C6198, Taufkirchen, Germany; 
 SantaCruz sc-130617, Heidelberg, Germany) 
pan- cytokeratin (Sigma C2562, Taufkirchen, Germany) 
GAP43 (SantaCruz sc-7457, Heidelberg, Germany) 
neurofilament   (DAKO M0762, Glostrup, Denmark) 
CD34 (SantaCruz sc-19621, Heidelberg, Germany) 
CD68 (SantaCruz sc-7082, Heidelberg, Germany) 
collagenIV (SantaCruz sc-11360, Heidelberg, Germany) 
fibronectin (DAKO A0245, Glostrup, Denmark) 
laminin (DAKO Z 0097, Glostrup, Denmark) 
Ki67 (SantaCruz sc-7844, Heidelberg, Germany) 
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2.5 Materials 
This is a series of 119 surgical specimens obtained during vitrectomy for idiopathic MP and 
idiopathic VMTS between January 2008 and April 2010. The specimens consisted of the ILM 
and epimacular tissue, and were removed en-bloc from 119 eyes of 117 patients including 79 
eyes with MP and 40 eyes with VMTS. Intraoperatively, the state of the vitreous was assessed. 
Regarding the presence of PVD, we divided all specim ns from eyes with MP into 2 groups: 
(1) 39 specimens were removed from eyes with MP and complete PVD; and (2) 40 specimens 
were removed from eyes with MP and incomplete PVD. 
 
All 119 specimens were processed for phase contrast microscopy, interference microscopy 
and cell nuclei staining. LIVE/ DEAD ® cell viability assay was performed in 27 specimens 
from 27 patients including 10 eyes with MP and complete PVD, 9 eyes with MP and 
incomplete PVD, and 8 eyes with VMTS. For immunocythemistry, 51 flat-mounted ILM 
specimens from 51 patients were processed including 16 eyes with MP and complete PVD, 16 
eyes with MP and incomplete PVD, and 19 eyes with VMTS. The remaining 40 specimens 
from 38 patients were only processed for phase contrast microscopy, interference microscopy 
and cell nuclei staining as mentioned above, because these specimens showed multiply folded 
during flat-mounted preparation appearing not suitable for immunolabeling procedures. 
(Table 2.1) 
 
The surgical procedure consisted of a three-port pars l na vitrectomy with en-bloc peeling of 
the ILM and the ERM. All patients were operated by experienced surgeons at the University 
Eye Hospital Munich. Forty-seven patients underwent a combined procedure of vitrectomy 
and cataract extraction. Only specimens presenting the ILM were included. Approval from the 
Institutional Review Board was obtained as well as the Informed Consent from each patient. 
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Table 2.1   Number of specimens processed by different methods 
Test 
MP with  
complete PVD 
(n=39) 
MP with 
incomplete PVD 
(n=40) 
 
VMTS 
(n=40) 
Phase contrast / interference microscopy 39 40 40 
Cell staining by DAPI 39 40 40 
LIVE/ DEAD ® cell viability assay 10 9 8 
Immunocytochemical analysis 16 16 19 
 
The surgical procedure of a three-port pars plana vitrectomy was performed as followed. 
Before opening the infusion line, the status of the posterior hyaloid was determined using a 
plano-concave contact lens. If the vitreous was partially attached to the retina, PVD was 
induced by suction with the vitrectomy probe over the optic disk. The posterior hyaloid was 
detached from the retina and excised up to the periph y. Then, peeling the ILM was 
performed using an end-gripping Eckardt forceps. To improve the precision of ILM peeling 
and to avoid incomplete removal, vital dyes had been applied during surgery: (1) BBG (0.5 
ml, 0.25%, Brilliant Peel; Fluoron GmbH, Neu-Ulm, Germany) was used to stain 20 
specimens from MP with complete PVD, 23 specimens from MP with incomplete PVD and 
26 specimens from VMTS; (2) MB (0.5ml, 0.15%, DORC, Dutch Ophthalmic Research 
Center Zuidland, the Netherlands) was used to stain2 specimens from MP with complete 
PVD and 1 specimen from VMTS; (3) TB  (0.5ml, 0.15%, DORC, Dutch Ophthalmic 
Research Center Zuidland, the Netherlands) was used only in 1 specimen from VMTS. 
Overall, vital dyes were administered in 73 eyes to visualize the ILM. In the remaining 46 
eyes, no intravitreal dye was used. In case of coexisting cataract, a combined procedure was 
performed. The ILM with epimacular tissue was harvested and processed for our study.  
 
The patients’ records were reviewed for age, gender, pr vious ocular surgery and preoperative 
history such as trauma. Additional information such as duration of symptoms was evaluated if 
available. 
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2.6 Methods     
2.6.1 Specimen fixation and flat-mounted preparation  
After removal, the excised tissue was immediately placed into a mixture of PFA for at least 
24 hours. Then, specimens were extended onto glass slide  as whole mounted membranes to 
show their maximum area by using fine-tipped forceps under a light microscope (Leica 
DM2500; Leica, Wetzlar, Germany). 
2.6.2 LIVE/ DEAD ® viability assay  
The LIVE/ DEAD ® Viability/ Cytotoxicity Kit (Invitrogen, Carlsbad, CA, USA) for 
mammalian cells test is to provide a two-color fluorescence cell viability assay. The 
polyanionic dye calcerin AM is well retained within all cells, producing an intense uniform 
green fluorescence in all cells (ex/em -495nm/ -515nm). Ethidium homodimer-1(EthD-1) is a 
high-affinity nuclei acid stain that is weakly fluorescent until bound to DNA emitting red 
fluorescence. As cell-impermeant viability indicator, EthD-1 can produce a bright red 
fluorescence in dead cells (ex/em -495nm/ -630nm), whereas it is excluded by the intact 
plasma membrane of live cells. This assay has been alr ady proved to be used to determine 
the percentage of dead and live cells. [Ammar, 2010]  
 
Due to the fluorescence microscope of our laboratory, in our study all cells were stained with 
blue color by calcerin AM, whereas dead cells were shown with red color by binding EthD-1. 
Based on the time of fixation in PFA, we had 2 groups in this assay: 21 specimens were 
immediately processed after surgical removal; and 6 specimens were processed 24 hours after 
surgical removal.  
 
After preparing ILM specimens as flat-mounted membranes, one drop (almost 100µl) of 
LIVE / DEAD ® reagent was added. Then specimens were incubated for 30 minutes, and a 
coverslip was mounted on glass slides. The fluorescence microscope Leica (Leica MS5; Leica, 
Wetzlar, Germany) was used for analysis at magnificat ons between x50 and x400. 
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2.6.3 Phase contrast and interference microscopy  
In phase contrast microscopy, differences in image contrast are produced by using an optical 
mechanism to translate subtle variations in phase into corresponding changes in amplitude 
[Lee, 2011]. Interference microscopy was applied to etect changes in surface height, such as 
cellular proliferation compared to bare ILM [Gandorfer, 2009]. Differences in image intensity 
are produced by splitting the entering light into two beams that pass through the specimen and 
become recombined in the image plane, where the interference effects make the transparent 
object details become visible [Duncan, 2011]. 
 
All 119 flat-mounted specimens were labeled with DAPI for cell nuclei staining. Specimens 
were analyzed using a modified fluorescence microscope (Leica MS5; Leica, Wetzlar, 
Germany) that enabled us to perform both interference and phase contrast microscopy at 
magnifications between x50 and x400.  
2.6.4 Immunocytochemistry 
After PFA fixation, the ILM specimens were rinsed with 0.1M PBS (pH7.4) 2 times for 5 
minutes and incubated with the pepsin for 30 minutes a  room temperature. Then specimens 
were rinsed with 0.1M PBS again 2 times for 5 minutes. The samples were blocked using 
normal donkey serum (dilution, 1: 20) in PBTA for 2 hours at room temperature. Afterward, 
they were rinsed with PBTA 3 times for 5 minutes and then incubated with primary 
antibodies (anti-CD34, -CD45, -CD68, -CD163, -collagen IV, -CRALBP, -pan-cytokeratin, -
fibronectin, -GFAP, -GAP43, -Ki67, -Kir4.1, -laminin, -NF, -vimentin) according to 
manufacturer’s instructions for 24 hours at the incubator (37°C). Since the maximum number 
of fluochromes used at one time was limited, and the antibody combinations were limited 
caused by the species they were originating from, we only used combinations of 3 antibodies.  
 
The membranes were rinsed with PBTA for 3 times and incubated with the secondary 
antibodies (anti- α-SMA, cy2, cy3, cy5) according to manufacturer’s intructions for 2 hours 
at room temperature. Then specimens were rinsed with PBTA 4 times for 10 minutes and with 
PBS 3 times for 5 minutes. As mentioned above, we used the combination of 3 antibodies. 
 
Finally, the specimens were prepared as flat-mounted m mbranes. One drop of antifading 
mounting medium DAPI was added. Then, specimens were placed onto the Crystal/ Moune 
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(Biomedia, California) with coverslip and viewed under the fluorescence microscope at 
magnifications between x50 and x400.  
 
For control specimens, primary antibodies were substit ted with diluent followed by 
incubation with secondary antibodies alone. All other procedures were identical to normal 
immunolabeling procedures. 
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2.7 Statistical analysis and photodocumentation 
Images, captured by a digital camera (ProgRes CF; Jenoptik, Jena, Germany), were analyzed 
measuring the specimen area in consideration of magnification by Adobe Photoshop CS4. 
Cell quantification was analyzed using ImageJ software, a Java-based image processing 
program developed at the National Institutes of Health [Gering, 2004]. The dead cell and total 
cell count were calculated by ImageJ. If the total cell count was less than 100, labeled nuclei 
were counted in fluorescence micrographs using ImageJ software with manual counting. If 
the total cell count was over 100, we used automatic counting. Finally, measured areas and 
cell counts of specimen parts were added up from each p tient.  
 
Statistical analysis of total cell counts and total area of specimens was performed using the 
computer software, Statistical Package for the Social Science (SPSS) version 16.0. Mann-
Whitney Test, Kruskal-Wallis-Test and Chi-Square Test were performed for evaluation. P< 
0.05 was considered to be statistically significant.
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3.  Results 
3.1 Clinical features 
Fifty-nine women and 58 men were included in this series, corresponding to 71 right eyes and 
48 left eyes. Two male patients underwent surgery on both eyes. The total of 119 specimens 
was divided into three groups: (1) specimens removed from eyes with MP and complete PVD 
(n = 39), (2) specimens removed from eyes with MP and incomplete PVD (n = 40), and (3) 
specimens removed from eyes with VMTS (n = 40). Thestate of the vitreous was 
intraoperatively confirmed during surgery.  
 
The average age at time of surgery was 69.3 years (ranged from 41 to 81 years), and the age 
distribution of patients was similar in all three groups of diagnosis. With regard to previous 
ocular surgery, 27 eyes had undergone cataract surgery with phacoemulsification and 
implantation of an intraocular lens, including 6 eyes with MP and complete PVD, 10 eyes 
with MP and incomplete PVD and 11 eyes with VMTS. The duration of symptoms according 
to the patients’ documents ranged from 3 weeks to more than 5 years. 
 
Among all 119 specimens, 73 samples were removed aft r administration of vital dyes into 
the vitreous cavity: BBG was used to stain 20 specim ns from MP with complete PVD, 23 
specimens from MP with incomplete PVD and 26 specimns from VMTS; MB was used to 
stain 2 specimens from MP with complete PVD and 1 specimen from VMTS; TB was used 
only in 1 specimen from VMTS, which was already mentioned above in section 2.5. 
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3.2 LIVE/ DEAD ® cell viability assay 
3.2.1 General features 
LIVE/ DEAD ® assay evaluation focused on a consecutive series of 27 specimens obtained 
during vitrectomy. In detail, 10 specimens from eyes with MP and complete PVD, 9 
specimens from eyes with MP and incomplete PVD, and 8 specimens from eyes with VMTS 
were tested. The distribution of patients’ age and gender involved in this series is shown in 
Table 3.1. Figure 3.1 presents dead cells as red cell nuclei and the amount of total cells as 
blue cell nuclei. 
 
The viability percentage showed a broad variety from 18% to 98% with a mean of 76.6% 
(standard deviation, SD 27.8%). The mean cell viability percentages were 94.5% (SD 4.8%) 
in specimens removed from eyes with MP and complete PVD, 56.4% (SD 28.9%) in 
specimens removed from eyes with MP and incomplete PVD, and 64.8% (SD 25.9%) in 
specimens removed from eyes with VMTS. We found significantly more viable cells in 
specimens from MP than in specimens from VMTS (p = 0.012, Mann-Whitney Test). 
Comparing specimens of MP with complete and incomplete PVD, there was a significant 
higher viability in specimens from eyes with MP and complete PVD (p = 0.014, Mann-
Whitney Test).  
 
Six specimens (including one specimen from MP with complete PVD, three specimens from 
MP with incomplete PVD and two specimens from VMTS) were tested 24 hours after 
surgical removal with meanwhile storage in BSS at +4°C. These specimens were found with a 
mean viability percentage of 83% (SD 28%), which ranged from 32% to 98%. 
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Table 3.1   LIVE/ DEAD ® viability assay and clinical data 
Case Gender Age Eye Diagnosis Dye 
Area 
(mm2) 
Total  
cells 
Live / 
Dead cell 
Viability 
(%) 
1 M 80 R MP-1 BBG 2.9 55 50/5 91 
2 M 74 R MP-1 - 5.5 1719 1418/3041 82 
3 F 68 R MP-1 - 5.0 841 810/31 96 
4 M 72 R MP-1 - 3.6 1734 1686/48 97 
5 M 81 R MP-1 BBG 2.4 663 632/31 96 
6 M 60 R MP-1 - 5.4 1018 906/110 89 
7 M 71 L MP-1 BBG 16.3 6595 6298/297 95 
  8* M 71 R MP-1 - 3.4 193 185/8 96 
9 F 70 R MP-1 - 26.9 7459 7174/285 96 
10 F 70 R MP-1 - 0.9 57 51/6 89 
11 M 74 R MP-2 - 0.6 49 35/14 71 
12 M 83 R MP-2 - 16.5 6365 5992/373 94 
 13* F 50 L MP-2 - 0.3 114 99/15 87 
 14* F 63 R MP-2 - 5.8 765 752/13 98 
15 M 81 L MP-2 BBG 7.5 1391 407/984 29 
16 F 44 R MP-2 BBG 10.4 137 109/28 80 
17 M 62 R MP-2 - 8.1 780 474/306 61 
18 F 66 R MP-2 - 23.1 7543 1876/5667 25 
  19* M 45 R MP-2 - 14 319 103/216 32 
20 F 76 L VMTS BBG 6.2 231 150/81 65 
21 F 76 L VMTS BBG 3.7 14 12/2 86 
22 M 75 L VMTS BBG 1.1 126 36/90 29 
23 F 62 L VMTS BBG 1.3 126 46/80 37 
24 M 65 L VMTS BBG 2.8 17 3/14 18 
 25* F 68 R VMTS - 2.7 446 389/57 87 
 26* M 72 R VMTS - 1.8 11 5/6 45 
27 F 74 R VMTS BBG 2.6 45 17/28 38 
 
(*) processed 24 hours after surgical removal; (M) Male, (F) Female; (BBG) Brilliant Blue G, 
(-) no dye; (MP-1) MP with complete PVD, (MP-2) MP with incomplete PVD. 
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Figure 3.1  
 
Figure 3.1 LIVE/ DEAD ® viability assay. A specimen removed from 
a patient with MP and incomplete PVD. (A) Dead cells bind to EthD-1 
presenting as bright red cell nuclei. (B) All cells were labeled with 
calcerin AM presenting as blue cell nuclei. (C) Interference micrograph 
and (D) phase contrast micrograph of the same detail as (A) and (B) 
demonstrating the cells’ distribution on the ILM. (Original 
magnification: x400) 
 
3.2.2 Cell viability percentage and vital dye Brilliant Blue G 
In this series, there were 11 specimens removed aftr using BBG administration into the 
vitreous cavity to stain the ILM during vitrectomy. In the remaining 16 cases, no dye was 
used to stain the ILM intraoperatively. By comparing the viability percentage of these two 
groups, it was found that specimens removed from eyes without BBG usage during surgery 
presented with significantly higher mean cell viability percentage (83%) than specimens with 
BBG dye (75%) (p = 0.048, Mann-Whitney Test). (Figure 3.2) 
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Figure 3.2  
 
 
Figure 3.2 Box plot presentation shows significantly higher cell viability 
percentage in specimens removed without administration of BBG during 
surgery compared to specimens removed after administration of BBG  into 
the vitreous cavity (p = 0.048, Mann-Whitney Test). 
 
 
3.2.3 Cell viability percentage and clinical data 
Specimens removed from 15 male and 12 female patients presented with average viability 
percentages of 86.7% and 64.6%, respectively.   
 
Comparing the cell viability with the patients’ age, the highest average viability percentage of 
94% was seen in the group of 70-80 year old (n = 12). Specimens from the group of 60-70 
years old patients (n = 8) were found with the lowest average cell viability percentage of 46%. 
 
Duration of symptoms in this series ranged from 3 weeks to more than 5 years. We found that 
duration of symptoms less than 6 months was correlated with the highest cell viability 
percentage of 93%. In contrast, specimens from patients with the duration of symptoms 
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ranging from 6 months to 1 year presented with the lowest cell viability percentage (42%). 
(Table 3.2) 
 
Table 3.2 Duration of symptoms and cell viability percentage 
Duration of symptoms Case numbers 
Mean cell viability  
percentage (%) 
< 3 months 4 93 
3-6 months 6 93 
6 months - 1 year 7 42 
1-3 years 4 76 
> 3 years 4 83 
Not mentioned 2 87 
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3.3 Phase contrast and interference microscopy  
Total cell count and cell distribution analysis included all 119 specimens. By phase contrast 
and interference microscopy, areas of the ILM presenting with cell proliferation were easily 
distinguished from areas without cell proliferation. The cell nuclei and cell extensions were 
clearly delineated from the ILM. Fluorescence micros opy showed the cell nuclei with blue 
color by DAPI stain. (Figure 3.3) 
 
Figure 3.3 
 
  Figure 3.3 Phase contrast and interference micrographs and DAPI cell nuclei 
staining from a specimen removed for MP with complete PVD. (A) Phase contrast 
micrograph, (B) interference micrograph and (C) DAPI nuclei staining image 
demonstrate cell proliferation and the cells’ distribution that can easily be detected 
and distinguished from areas with bare ILM (asterisk). (Original magnification: 
x200) 
 
3.3.1 Total cell count and removed area of the ILM  
All 119 specimens showed a large variety of total cell ount that ranged from 0 to 20,778 with 
a mean of 2,550 (SD 3,930). Cell counts in specimens with homogenous cell distribution was 
4,489 (SD 4,754) compared to 1,298 (SD 1,168) in specimens with cell clusters. The total 
area of ILM ranged from 0.3 mm2 to 31.3 mm2 with a mean of 8.8 mm2 (SD 7.5 mm²). 
 
Specimens from eyes with MP and complete PVD seem to prevail to from eyes with MP and 
incomplete PVD and VMTS. However, in terms of total ce l count and removed area of ILM 
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the difference was not statistically significant among the three groups of diagnosis (P > 0.05, 
Kruskal-Wallis-Test). (Table 3.3) 
 
Table 3.3  Average areas of removed ILM and total cell counts according to the groups of 
diagnosis 
Diagnosis 
Case 
numbers 
Average area 
of ILM (mm2) 
Average total 
cell count 
MP with complete PVD 39 9.8 3,574 
MP with incomplete PVD 40 9.0 2,444 
VMTS 40 7.6 1,658 
 
 
3.3.2 Cell distribution patterns 
In almost half of all 119 cases (n = 59) examined for cell count and cell distribution analysis, 
cell proliferation was seen as a continuous sheet of cells homogenously distributed on the 
ILM (Figure 3.4). In the remaining 59 specimens, the cells were inhomogenously distributed 
at the ILM forming areas of cell clusters (Figure 3.5). One specimen from MP with complete 
PVD was found without cell proliferation but bare ILM. 
 
Excluding the specimen removed from MP and complete PVD with bare ILM, 58.9% 
specimens removed from MP and complete PVD (22/38), 52.5% specimens removed from 
MP and incomplete PVD (21/40) and 40% specimens remov d from VMTS (16/40) were 
distributed homogenously. 
 
Specimens from eyes with MP showing homogenous cell distribution were seen with 
significantly more total cell counts (p < 0.001, Mann-Whitney Test) and larger specimen 
areas (p = 0.006, Mann-Whitney Test) than specimens r moved from eyes with MP showing 
inhomogenous cell distribution with cell clusters. (Table 3.4)  
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Table 3.4  Cell distribution patterns with total cell counts and ILM areas  
Cell 
distribution 
Diagnosis 
Cases 
number 
Mean area 
of ILM (mm2) 
Mean total 
cell count 
MP with complete PVD 16 6.1 995 
MP with incomplete PVD 19 5.8 490 inhomogenous 
VMTS 24 6.0 517 
MP with complete PVD 22 12.7 5567 
MP with incomplete PVD 21 11.9 4212 homogenous  
VMTS 16 9.9 3370 
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Figure 3.4  
 
 
Figure 3.4 Homogenous cell distribution patterns in a specimen removed for VMTS. 
(A, C) DAPI cell nuclei staining fluorescence microg aph shows a continuous sheet 
of homogenously distributed cells on the flat-mounted ILM, (B) phase contrast 
micrograph and (D) interference micrograph present the same detail of the 
specimens. (Original magnification: A, B: x50; C, D: x200)
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Figure 3.5 
 
 
Figure 3.5 Inhomogenous cell distribution patterns with cell cluster formation in a 
specimen removed for MP with incomplete PVD. (A, C) DAPI cell nuclei staining 
fluorescence micrographs demonstrate large cell cluster with densely packed cell 
proliferation (arrow), (B) phase contrast micrograph and (D) interference 
micrograph images show corresponding details of the same specimens. Cell cluster 
formation (arrow) sharply delineates directly neighboring bare ILM (asterisk). 
(Original magnification: A, B: x50; C, D: x200) 
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3.4 Immunocytochemical analysis  
3.4.1   General features 
Twenty-seven specimens were processed by indirect immunocytochemical analysis, including 
8 specimens from eyes with MP and complete PVD, 8 specimens from eyes with MP and 
incomplete PVD, and 11 specimens from eyes with VMTS.  
 
Most positive immunostaining of anti-GFAP, -CD163 and –CD45, and anti-α SMA was 
found in all specimens tested. Due to their predominant expression, the four antibodies were 
analyzed in detail in section 3.4.2. 
 
As presented in Table 3.5 and Figure 3.6, anti-CRALBP and -vimentin were positive in all 
three groups of diagnosis. Anti-Kir4.1 was absent in VMTS specimens but sparsely 
distributed in specimens from MP. Anti-pan-cytokeratin was only present in one specimen 
removed from eye with VMTS; whereas, anti-GAP43 and-NF were not seen in this series. 
Anti-CD34 was sparsely positive in all specimens tested. Anti-CD68 was mostly 
demonstrated in VMTS (about 50%), but absent in specim ns from MP with complete PVD. 
Collagen IV and fibronectin antigens were expressed in all samples. Anti-laminin was 
sparsely distributed in MP, irrespectively of the pr sence of complete or incomplete PVD. In 
contrast, anti-Ki67 was sparsely distributed in VMTS (less than 30%), but positive in more 
than 60% specimens removed from eyes with MP.  
 
There were a proportion of cells not labeling with any cell marker combinations used in this 
study. These unidentified cells were negative for all cell type-specific antibodies used 
according to Table 3.5. Negatively labeled cells were mostly found loosely distributed as 
single cells at the ILM.  
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Table 3.5       Antibody expression according to diagnosis 
Positive labeled cells expressed in 
Anti- MP with 
complete PVD 
(n = 8) 
MP with 
incomplete PVD 
(n = 8) 
 
VMTS 
(n = 11) 
CD163 + + + 
CD45 + + + 
GFAP + + + 
Vimentin (+) + + 
CRALBP + + + 
Kir4.1 (+) (+) - 
α-SMA + + + 
pan-Cytokeratin - - (+) 
GAP43 - - - 
NF - - - 
CD34 (+) (+) (+) 
CD68 - (+) + 
Collagen IV + + + 
Fibronectin + + + 
Laminin (+) (+) + 
Ki67 + + (+) 
 
- absent；(+)  sparse;  + present 
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Figure 3.6  
 
 
Figure 3.6 Immunoreactivity of all 16 antibodies used in this study. Except for negative 
signals in anti-GAP43 and anti-neurofilament labeling, all antibodies demonstrated 
positive immunoreactivity that was at least sparsely distributed on flat-mounted ILM 
specimens. (Original magnification: Anti-CD163 x200, Anti-CD45 x400, 
Anti-GFAP x400, Anti-CRALBP x400, Anti-Kir4.1 x200, Anti-vimentin x100,  
Anti-alpha SMA x200, Anti-pan-cytokeratin x200, Anti-GAP43 x400,  
Anti-neurofilament x200, Anti-CD34 x400, Anti-CD68 x400, Anti-collagen IV x400,  
Anti-fibronectin x400, Anti-laminin x400, Anti-Ki67 x400) 
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3.4.2   Antigen expression of CD163, CD45, GFAP and α-SMA  
Immunocytochemical analysis of anti-CD163, -CD45, -GFAP, - and -α-SMA labeling was 
performed in the 24 specimens. According to Table 3.6, we found that (1) anti-CD163 
labeling presented predominantly in MP with complete PVD compared to other groups of 
diagnosis; (2) α-SMA labeling mainly presented in MP with incomplete PVD and VMTS; (3) 
anti-GFAP labeling was found in both MP groups, irrespectively of the extent of PVD; and (4) 
anti-CD45 expressions were similar in all three groups of diagnosis. 
 
Table 3.6  Detailed antibody analysis according to diagnosis 
Antibody-labeled cells expression in 
Anti- 
MP with 
complete PVD 
(n=8) 
MP with incomplete 
PVD 
(n=8) 
VMTS 
(n=8) 
CD163 ++ + + 
CD45 + + + 
GFAP ++ ++ + 
α-SMA + ++ ++ 
 
- absent；(+)  sparse; + some; ++ many 
 
3.4.3   Simultaneous cell-type specific antigen expression  
Most importantly, there were co-localizations of cell type specific antibodies seen, including 
anti-GFAP/CD45, anti-GFAP/CD163, anti-CD163/CD45, and anti-CD163/α-SMA (Figure 
3.7).  
 
When labeled with anti-GFAP, anti-CD45 was concomitantly co-localized with anti-GFAP. 
We found co-localization of these two antibodies in almost 20% specimens tested. Co-
localizations of anti-CD163/GFAP and anti-CD163/CD45 were sparsely present. (Figure3.8) 
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Co-localization of anti-CD163 and anti-α-SMA was only seen in single cases. There was no 
apparent co-expression of α-SMA and GFAP or α-SMA and CD45 in any specimens 
examined. Other cell markers such as anti-CRALBP and –vimentin were simultaneously 
expressed in 67% of tested specimens. However, there was no evidence of co-localization of 
anti-CRALBP or –vimentin with anti-GFAP.  
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Figure 3.7 
 
  
Figure 3.7 Fluorescence micrographs demonstrating antibody co-localizations according 
to their antibody combinations tested and in combinatio  with a merged figure with 
DAPI cell nuclei staining. (A) Co-localization of anti-GFAP/CD45 with different 
labeling patterns of anti-α SMA. (B) Co-localization of anti-CD163/α-SMA with 
negative labeling of anti-GFAP. (C) Co-localization f anti-GFAP/CD163 and anti-
GFAP/CD45. (D) Co-localization of anti-CRALBP/vimentin. (Original magnification: 
(A) x50; (B) x400; (C) x200; (D) x400) 
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Figure 3.8 
 
 
Figure 3.8 Fluorescence micrographs of anti-CD163, -CD45 and –GFAP 
labeling. In contrast to other specimens, this specim n shows positive 
immunoreactivity for anti-CD163, whereas anti-CD45 and -GFAP were 
negative. (Original magnification: x400) 
 
3.4.4   Negative control  
Whenever more than two parts of specimens from one pati nt were obtained, we were able to 
perform indirect immunofluorescence evaluation with more than one combination of three 
antibodies. In all control specimens, when the prima y antibody was substituted by diluent, no 
immunoreactivity was observed. (Figure 3.9) 
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Figure 3.9 
 
 
Figure 3.9 Fluorescence micrographs of negative controls of immunocytochemical 
labeling. (Original magnification: Anti-CD163 x50, Anti-CD45 x50, Anti-GFAP x100, 
Anti-CRALBP x400, Anti-Kir4.1 x50, Anti-vimentin x200, Anti-alpha SMA x400, Anti-
pan-cytokeratin x50, Anti-GAP43 x50, Anti-neurofilament x100, Anti-CD34 x50, Anti-
CD68 x50, Anti-collagen IV x200, Anti-fibronectin x50, Anti-laminin x50, Anti-Ki67 
x200) 
Discussion 
53                                                                                                                                                                               
4.  Discussion 
4.1 Flat-mount preparation  
Since ILM peeling with ERM removal became a routine approach to relieve vitreomacular 
traction during vitreoretinal surgery, harvested ILM specimens were conventionally processed 
for embedding and sectioning preparation procedures in the past. Recently, a new preparation 
technique was proposed, the flat-mounted specimen preparation method, and a relatively few 
numbers of ILM specimens were studied using this method to date. [Hisatomi, 2005; 
Hisatomi, 2006; Gandorfer, 2009] 
 
The flat-mount preparation method has numerous advantages compared to conventional 
cross-sectioning preparation procedures. Most importantly, by mounting whole ILM 
specimens on a glass slide the new method enables to show the maximum area of a tissue 
specimen with en-face observation of the total cell distribution. Not a single cell is missed to 
be analyzed. In contrast, by conventional serial sectioning of ILM specimens a relatively 
small part of the ILM specimen is seen. Gandorfer and colleagues assumed that no more than 
6% of the total peeled ILM area would be investigated under the microscope by serial 
sectioning preparation of ILM specimens. [Gandorfer, 2009] Thus, only a minor part of the 
specimen is analyzed possibly missing important details. Using the flat-mount preparation 
procedure in a large number of specimens, stage II macular holes were reported for the first 
time to present cell proliferation on the ILM in all cases. [Schumann, 2011] Most probably, 
epiretinal cell proliferation was missed in earlier studies using embedding and cross-section 
techniques. Using the new preparation method, surgical specimens were screened for pores in 
the ILM since cross-section preparation of ILM specimens does not allow for determining the 
incidence of ILM pores regarding the small area of interest. [Gandorfer, 2011] Thereby, it 
became possible to demonstrate that ILM pores are rath r a rare finding and that they are less 
frequently found than formerly presumed.  
 
Furthermore, cell proliferation in flat-mounted ILM specimens can be easily examined by 
different techniques without changing the protocol. Interference microscopy and phase 
contrast microscopy are performed without additional tissue staining. Time consuming 
embedding procedures are not needed. Immunocytochemi al staining techniques can be 
processed on flat-mounted specimen, thus allowing for direct correlation of microscopic 
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findings with cell-specific immunoreactivity. Cell nuclei staining and live-dead cell viability 
testing are possible to obtain accurate results analyzi g cell distribution and the cells’ viability. 
Of note, after analysis, flat-mounted ILM specimens can still be processed for further 
embedding and cross-sectioning procedures, such as transmission electron microscopy, 
according to conventional protocols. 
 
However, the new flat-mounted specimen preparation pr cedure does have some limitations 
with regard to morphological topography and variety of immunocytochemical antibody 
combinations. By microscopic analysis of flat-mounted ILM specimens, it is not yet possible 
to determine if cellular elements are adjacent to the vitreal or to the retinal side of the ILM. 
The amount and the type of collagen at the ILM and within cell proliferations can not be 
specified by interference or phase contrast microscope alone. Immunocytochemical analysis 
helps to identify the type of collagen although with our laboratory setting no more than three 
antibody combinations could be tested at once. 
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4.2 Cell viability 
This is the first study performing cell viability investigation of ILM specimens. Whereas in 
embedding and sectioning techniques numerous fixatives and solutions become necessary to 
process the surgically removed tissue, in flat-mount preparation native tissue can be examined. 
This allows for new applications and purposes in studying cell proliferation of ILM 
specimens.  
 
Comparing specimens removed from eyes with MP or VMTS, we found significant 
differences in cell viability. Specimens removed from eyes with MP (76.9%) presented with 
higher cell viability than specimens removed from eyes with VMTS (64.8%). In detail, 
specimens from MP with complete PVD (94.5%) were found with significantly higher cell 
viability than specimens from MP with incomplete PVD (56.4%). These findings raise the 
hypothesis that the extent of PVD or vitreoretinal adhesion with traction forces may have 
some influence on cell viability of epiretinal cells, although a causative correlation can not be 
determined by this study. Cell viability measurements assess healthy cells in tissue 
independent if these cells are actively dividing or if they are quiescent. Of note, cell viability 
analysis provides no information on proliferation potential. The fact that epiretinal 
membranes from eyes with complete PVD show significantly more viable cells than eyes with 
persistent vitreoretinal adhesion or even antero-posterior vitreoretinal traction may be due to a 
higher cell turnover in the latter ones. One might hypothesize that severe vitreoretinal traction 
modulates tissue homeostasis in epiretinal membranes which is a dynamic balance between 
cell growth, cell proliferation and cell death in order to regulate morphology and function. 
[Meth, 2000] However, further investigations with measurement of cell proliferation and 
apoptosis are needed to elucidate that question. 
 
One might argue that differences in cell viability percentages of specimens removed from MP 
or VMTS may be due to discontinuity of specimen preparation, although we defined tissue 
processing immediately after surgical removal precis ly using the same procedure. To 
improve our understanding of cell death and cell viabil ty after ILM/ ERM peeling, we 
examined six specimens with a time delay of 24 hours after their removal with meanwhile 
storage in BSS at +4°C. These specimens were expected to present lower cell viability 
percentages than specimens immediately processed after surgery. Interestingly, these six 
specimens (one specimen from MP with complete PVD, three specimens from MP with 
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incomplete PVD,  and two specimens from VMTS) were found with a mean viability 
percentage of 83% (SD 28%) that ranged from 32% to 98%. Since time delay in specimens’ 
preparation did not significantly lowered cell viability, we assume that difference in 
specimens removed from MP and VMTS as reported above are rather related to disease 
characteristics than to tissue processing. 
 
Furthermore, our results demonstrate that epiretinal tissue removed after intraoperative 
administration of BBG (75%) presents significantly lower cell viability that epiretinal 
membranes removed without using BBG (83%) as vital dye during vitreoretinal surgery. 
Brilliant blue G was always considered to be a safevital dye without retinal toxicity when 
applied in low dose for a short period of time in routine settings. [Schumann, 2009; 
Schumann, 2010; Morales, 2010; Haritoglou, 2011; Hönig, 2011] In clinical studies, there 
was no retinal toxicity or adverse effects related to the BBG reported. Therefore, BBG 
became generally accepted in routine macular surgery for specific ILM staining. However, 
this is the first study comparing cell viability ofremoved ILM/ERM specimens with and 
without administration of BBG during vitrectomy. Based on our results, it appears that BBG 
may have some effect on epiretinal cells even in routine surgical setting. 
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4.3 Cell distribution patterns 
In accordance to previous studies, we found massive cell proliferation in ILM specimens 
removed during macular surgery for MP and VMTS. [Heidenkummer, 1992; Gastaud, 2000; 
Gandorfer, 2005; Sebag, 2007; Schumann, 2010] However, cell count and cell distribution of 
ILM/ERM specimens have not been analyzed before by flat-mount preparation although 
morphological studies precisely described cell proliferations in MP and VMTS by sectional 
preparation in the past. 
 
Herein, we report that specimens removed from eyes with MP, irrespective of the presence of 
PVD, presented with significantly higher total cell counts than specimens removed from eyes 
with VMTS. However, given the fact that we found a large variety of removed specimen 
areas in both diseases, total cell numbers remain difficult to interpret. Importantly, we found 
two cell distribution patterns in specimens removed from MP and VMTS, the homogenous 
cell distribution and the cell cluster formation. Both distribution patterns were reported in flat-
mounted ILM specimens removed from eyes with idiopathic macular holes as well. 
[Schumann, 2011] In this study, specimens from MP demonstrated both distribution patterns 
that showed no difference comparing specimens removd from eyes with complete or 
incomplete PVD. In specimens from VMTS, cell cluster formation was more frequently 
(24/40 specimens) found than homogenous cell distribution. One might speculate if epiretinal 
cell proliferation may be initiated by localized vitreoretinal traction forming cell clusters that 
progress to homogenous cell multilayers at the vitral side of the ILM. In that context, retinal 
Müller glial cells are thought to become activated by vitreoretinal traction. It is hypothesized 
that activated RMCs migrate through the ILM on its vi real surface where they are believed to 
form epiretinal cell proliferations. [Bringmann and Wiedemann, 2009]  
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4.4 Antigen expression 
4.4.1 General expression 
In order to determine the pathologic relation betwen the vitreous, the retina and epiretinal 
tissue, numerous studies described morphological featur s of ERMs in detail. [Hiscott, 1983; 
Smiddy, 1989; Heidenkummer, 1996; Schumann, 2010] Immunohistochemical examinations 
were performed by cross-sectional preparation techniques to add information on cell types 
and the cells’ origin involved in ERM formation in MP and VMTS. [Hiscott, 1984; 
Heidenkummer, 1992; Shinoda, 2000] However, this is the first study reporting on antigen 
expression in a large series of flat-mounted ILM/ERM specimens removed from MP and 
VMTS. Herein, we present evidence that glial cells and hyalocytes seem to be predominant in 
epimacular tissue from MP and VMTS. 
 
Glial cell marker such as GFAP, vimentin and CRALBP were demonstrated in specimens 
from MP and VMTS, irrespective of the presence of PVD. Glial fibrillary acidic protein 
constitutes of glial intermediate filaments in astrocytes of the retina. It is not or very faintly 
expressed in RMCs, except at their endfeet. However, in pathologic conditions RMCs become 
activated. Thereby, they were shown to up-regulate GFAP in response to injury or stress, such 
as tractional forces mediated from the vitreous to the retina. [Uhlmann, 2003; Bringmann, 
2006] Retinal Müller glial cells, normal and reactive astrocytes are also known to be positive 
for vimentin. [Nakazawa, 2007; Luna, 2010] Kir4.1 is found on RMC endfeet membranes. 
[Higashimori, 2007; Ruiz-Ederra, 2007] Furthermore, RMCs as well as RPE cells were 
demonstrated to be immunoreactive for CRALBP. [Collery, 2008; Huang, 2009] In this study, 
immunostaining for pan-cytokeratin was negative in MP and sparsely positive in VMTS. 
Kir4.1 was found positive in MP. Vimentin and CRALBP were seen in MP and VMTS in 
similar distribution. Thus, we postulate that rather glial cells than RPE cells predominated in 
our specimens. This is in contrast to previous studies reporting on the presence of RPE cells 
in idiopathic MP, and demonstrating the absence of RPE cells in VMTS. [Smiddy, 1989; 
Shinoda, 2000] Based on our results, we support the hypothesis that glial cells, notably RMCs, 
are an important component of epiretinal membranes in both MP and VMTS which is in 
accordance to previous ultrastructural and immunohist chemical findings. [Hiscott, 1983; 
Shinoda, 2000; Gastaud, 2000; Snead, 2004] 
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Hyalocyte marker such as CD45 and CD163 were similarly demonstrated in specimens from 
MP and VMTS in this study. Hyalocytes are known to be immunoreactive for CD45, CD64 
and CD163, to belong to the monocyte/macrophage lineage, and to derive from bone marrow. 
[Lazarus, 1994; Zhu, 1999; Sakamoto, 2003; Qiao. 2005; Sakamoto, 2011] According to their 
morphology, hyalocytes are described as resembling macrophages. However, a variety of 
morphological features of hyalocytes can be found in cells of the same population. It is 
questionable, if this heterogeneity is related to different origins of cells or to different states of 
cell metabolism and activity. Being rather a heterog neous population of cells, hyalocytes 
were reported to be replaced in the vitreous within seven months under physiological 
conditions. [Qiao, 2005] 
 
Myofibroblast-like cells, being immunoreactive for α-SMA, represent contractile properties of 
epiretinal tissue possibly as a consequence of cell transdifferentiation. In this study, they were 
more frequently found in specimens from VMTS and MPwith incomplete PVD than in 
specimens from MP with complete PVD. Myofibroblast-like cells are of unknown origin 
possessing contractile elements. They are typically found in ERMs from VMTS as reported in 
the past. [Shinoda, 2000; Gandorfer, 2002; Gandorfer, 2005] However, myofibroblasts are not 
restricted to membranes derived from VMTS, but rather can be found in all epiretinal tissue 
that exerts traction at the retina such as ERMs in macular holes, diabetes retinopathy, and 
idiopathic MP. [Smiddy, 1992; Abu El-Asrar, 2006; Schumann, 2006; Schumann, 2008] 
 
The cell surface marker CD68 characterizes macrophages nd microglia. [Elner, 1992; Streit, 
2001; Zeng, 2008; Akrami, 2011] In this study, CD68 was demonstrated in VMTS and MP 
with incomplete PVD. CD68 was not found in specimens from MP with complete PVD. 
There is no cell-specific marker to differentiate between vitreous derived macrophages and 
retinal microglia. With regard to our results, it appears that vitreoretinal traction might be 
related to the presence of macrophages or microglia in ERMs.  
 
CD34 is known to be expressed in endothelial cells of retinal and choroidal blood vessels. 
[Barcelona, 2010] Since anti-CD34 was sparsely positive in all specimens tested in this study, 
we speculate that endothelial cells or endothelial precursor cells do not compose a major 
component of epiretinal tissue in MP and VMTS. 
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Collagen IV, fibronectin and laminin was found in all specimens removed from eyes with MP 
and VMTS that were examined in this study, which is in accordance with numerous previous 
reports. [Lesnik Oberstein, 2008; Ponsioen, 2008; Chen, 2009; Li, 2009]  
 
The proliferation marker Ki67 was positive in more than 60% of all tested specimens from 
eyes with MP in this study, but it was sparsely expr ssed in VMTS (below 30%). However, 
we found no evidence to specify the exact cell types which was related to the limitation of 
three antibody combinations.  
 
Anti-GAP43 and -NF were not seen in this series which is in contrast to previous 
examinations. [Sethi, 2005; Ivanov, 2006; Chen, 2008; Gandorfer, 2009; Lesnik Oberstein, 
2011] Anti-NF labelled processes were demonstrated in i iopathic epiretinal membranes 
representing neurites that were presumed to originate from retinal ganglion cells. [Lesnik-
Oberstein, 2008] GAP-43 expression was reported to be up-regulated in retinal ganglion cells 
and reactive RMCs upon retinal injury indicating that there is remodelling with some 
neuronal plasticity after retinal damage. [Dijk, 2007] However, the findings of this study do 
not support this hypothesis.   
 
Since a proportion of cells were not labeled with any cell marker combination used in this 
study, we presume there are either (1) cells that are non-viable, or (2) dedifferentiated 
progenitor cells, or (3) transdifferentiated cells that were not detected by the commonly used 
immunocytochemical antibodies. Cell transdifferentiation still complicates the determination 
of the cells’ phenotype and origin, because there is no specific marker of it. 
4.4.2 Simultaneous antigen expression 
Co-localizations of the glial cell marker anti-GFAP and the hyalocyte markers anti-CD45 and 
anti-CD163 as demonstrated in this study have not been described before in human ILM-
specimens removed for MP and VMTS. Furthermore, we found co-localization of anti-α
SMA with the hyalocyte marker anti-CD163. Other co-localizations that were observed in this 
study such as anti-CD163/CD45 and anti-CRALBP/vimentin have not been demonstrated in 
flat-mounted ILM specimens so far, but they are an expected finding according to previous 
reports on hyalocyte and glial cell antigen expressions. [Guérin, 1990; Lazarus, 1994; 
Sakamoto, 2003; Sakamoto, 2011] 
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Co-localization of hyalocyte and glial cell markers was recently described in ILM specimens 
removed from idiopathic macular holes. [Schumann, 2011] It appears that GFAP labeling in 
epiretinal cell proliferation needs to be reconsidere  since positive GFAP labeling no longer 
allows for determination of cells to be of glial origin. There are two hypotheses that may arise 
considering our findings. First, cells with double labeling for anti-GFAP and hyalocyte 
markers may represent hyalocytes. Hyalocytes with positive GFAP expression have already 
been described in other species. GFAP-positive hyaloc tes were reported in porcine, 
pecteneal, and bovine hyalocyte cell lines. [Nishitsuka, 2007; Llombart, 2009; Kohno, 2009] 
However, it is unknown if these ‘hyalocytes’ express d GFAP endogenously or if they 
contained GFAP from other origin due to their well-known phagocytic activity. Another 
hypothesis is that double labeled cells may represent progenitor cells.  
 
Co-localization of anti-CD163/α-SMA indicates that hyalocytes may transdifferentiate into 
myofibroblast-like cells. Myofibroblast-like transdifferentiation with positive α-SMA 
expression has been shown for both glial cells and hyalocytes. [Hirayama, 2004; Kohno, 2009; 
Sakamoto, 2011] Thus, our results support the hypothesis that hyalocytes are able to 
transdifferentiate into myofibroblast-like cells in epiretinal membranes.  
4.4.3 Contractility and posterior vitreous detachment 
Wrinkling of the ILM with underlying retinal layers i  a consistent feature in traction 
maculopathies such as MP and VMTS. Epiretinal cell pro iferation with contractile properties 
is generally accepted as a morphological correlate in he formation of tangential traction at the 
retina. [Morris, 2000] Most important, contractile elements in epiretinal tissue are presumed 
to be myofibroblasts. [Hiscott, 1983; Shinoda, 2000]  
 
As mentioned above, positive α-SMA labeled epiretinal cells mainly presented in MP with 
incomplete PVD and VMTS compared to MP with complete PVD. Thus, we hypothesize that 
the extent of PVD with persistent vitreoretinal adhesions may play an important role in the 
differentiation of epiretinal cells and their antigen expression in eyes with MP and VMTS. 
Persistent vitreoretinal adhesions due to incomplete PVD cause antero-posterior vitreoretinal 
traction at the ILM and retinal layers. [Koerner, 1999; Gandorfer, 2005; Sebag, 2008] It has 
previously been proposed that retinal Müller cells become activated by antero-posterior 
vitreoretinal traction in the context of incomplete PVD. [Bringmann, 2006] They are thought 
to migrate from the retinal onto the vitreal side of the ILM, where they consequently 
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proliferate and form epiretinal membranes. However, hyalocytes were not yet reported to 
become influenced by vitreoretinal traction, thereby changing their phenotype with α-SMA 
expression. Since this study presents microscopic observations but no causative correlations, 
further investigation is needed to elucidate the influence of persistent vitreoretinal adhesions 
on the behavior of epiretinal cells. 
 
4.5 Future prospects 
Previous studies have shown that Müller glial cells xpress the neuronal progenitor cell 
marker nestin in human retina. [Luna, 2010] Microglia and macroglia were reported to derive 
from one progenitor cell, and to derive from bone marrow mesenchymal stem cells expressing 
variable amounts of GFAP. [Fedoroff, 1997; Zhang, 2004] For a more detailed understanding 
of transdifferentiation and the cells’ origin, further investigations of epiretinal cell 
proliferation will be needed. Detection of neuronal progenitor cells in epiretinal membranes 
may be of importance and should be addressed in the future.  
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